Circulating interleukin-6 and cancer: A meta-analysis using Mendelian randomization

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Tian, Geng ^a   Mi, Jia ^a   Wei, Xiaodan ^a   Zhao, Dongmei ^a   Qiao, Lingyan ^a   Yang, Chunhua ^a   Li, Xianglin ^a   Zhang, Shuping ^a   Li, Xuri ^a   Wang, Bin ^a  

^a BINZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

IL6 PROTEIN, HUMAN; INTERLEUKIN 6;

ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HUMAN; LIVER NEOPLASMS; META ANALYSIS; RANDOMIZATION; SINGLE NUCLEOTIDE POLYMORPHISM;

ASIAN CONTINENTAL ANCESTRY GROUP; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INTERLEUKIN-6; LIVER NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; RANDOM ALLOCATION;

EID: 84934943545     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep11394     Document Type: Article

References (94)

1. Heikkila, K., Ebrahim, S. & Lawlor, D. A. Systematic review of the association between circulating interleukin-6 (IL-6) and cancer. Eur J Cancer 44, 937-945 (2008).
2. Bochud, M. & Rousson, V. Usefulness of Mendelian randomization in observational epidemiology. Int J Environ Res Public Health 7, 711-728 (2010).
3. Timpson, N. J. et al. Does greater adiposity increase blood pressure and hypertension risk?: Mendelian randomization using the FTO/MC4R genotype. Hypertension 54, 84-90 (2009).
4. Brennan, P. et al. Obesity and cancer: Mendelian randomization approach utilizing the FTO genotype. Int J Epidemiol 38, 971-975 (2009).
5. Belluco, C. et al. -174 G> C polymorphism of interleukin 6 gene promoter affects interleukin 6 serum level in patients with colorectal cancer. Clin Cancer Res 9, 2173-2176 (2003).
6. Mandal, S., Abebe, F. & Chaudhary, J. -174G/C polymorphism in the interleukin-6 promoter is differently associated with prostate cancer incidence depending on race. Genet Mol Res 13, 139-151 (2014).
7. Moreira, P. R. et al. Interleukin-6 expression and gene polymorphism are associated with severity of periodontal disease in a sample of Brazilian individuals. Clin Exp Immunol 148, 119-126 (2007).
8. Malaponte, G. et al. IL-6-174 G> C and MMP-9-1562 C > T polymorphisms are associated with increased risk of deep vein thrombosis in cancer patients. Cytokine 62, 64-69 (2013).
9. Talar-Wojnarowska, R. et al. Clinical significance of interleukin-6 (IL-6) gene polymorphism and IL-6 serum level in pancreatic adenocarcinoma and chronic pancreatitis. Dig Dis Sci 54, 683-689 (2009).
10. Slattery, M. L. et al. Genetic variants in interleukin genes are associated with breast cancer risk and survival in a genetically admixed population: the Breast Cancer Health Disparities Study. Carcinogenesis 35, 1750-1759 (2014).
11. Cil, E. et al. Interleukin-10-1082 gene polymorphism is associated with papillary thyroid cancer. Mol Biol Rep 41, 3091-3097 (2014).
12. Tindall, E. A. et al. Interleukin-6 promoter variants, prostate cancer risk, and survival. Prostate 72, 1701-1707 (2012).
13. Giannitrapani, L. et al. IL-6-174G/C polymorphism and IL-6 serum levels in patients with liver cirrhosis and hepatocellular carcinoma. OMICS 15, 183-186 (2011).
14. Gaur, P., Mittal, M., Mohanti, B. & Das, S. Functional variants of IL4 and IL6 genes and risk of tobacco-related oral carcinoma in high-risk Asian Indians. Oral Dis 17, 720-726 (2011).
15. Abuli, A. et al. Case-control study for colorectal cancer genetic susceptibility in EPICOLON: previously identified variants and mucins. BMC Cancer 11, 339 (2011).
16. Ognjanovic, S. et al. Serum CRP and IL-6, genetic variants and risk of colorectal adenoma in a multiethnic population. Cancer Causes Control 21, 1131-1138 (2010).
17. Hawken, S. J. et al. The utility and predictive value of combinations of low penetrance genes for screening and risk prediction of colorectal cancer. Hum Genet 128, 89-101 (2010).
18. Dossus, L. et al. PTGS2 and IL6 genetic variation and risk of breast and prostate cancer: results from the Breast and Prostate Cancer Cohort Consortium (BPC3). Carcinogenesis 31, 455-461 (2010).
19. Cacev, T., Jokic, M., Loncar, B., Krizanac, S. & Kapitanovic, S. Interleukin-6-174 G/C polymorphism is not associated with IL-6 expression and susceptibility to sporadic colon cancer. DNA Cell Biol 29, 177-182 (2010).
20. Vasku, A., Vokurka, J. & Bienertova-Vasku, J. Obesity-related genes variability in Czech patients with sporadic colorectal cancer: preliminary results. Int J Colorectal Dis 24, 289-294 (2009).
21. Tsilidis, K. K. et al. Association of common polymorphisms in IL10, and in other genes related to inflammatory response and obesity with colorectal cancer. Cancer Causes Control 20, 1739-1751 (2009).
22. Slattery, M. L. et al. Colon tumor mutations and epigenetic changes associated with genetic polymorphism: insight into disease pathways. Mutat Res 660, 12-21 (2009).
23. Ozgen, A. G. et al. The (-174) G/C polymorphism in the interleukin-6 gene is associated with risk of papillary thyroid carcinoma in Turkish patients. J Endocrinol Invest 32, 491-494 (2009).
24. Ognjanovic, S., Yuan, J. M., Chaptman, A. K., Fan, Y. & Yu, M. C. Genetic polymorphisms in the cytokine genes and risk of hepatocellular carcinoma in low-risk non-Asians of USA. Carcinogenesis 30, 758-762 (2009).
25. Gangwar, R., Mittal, B. & Mittal, R. D. Association of interleukin-6-174G> C promoter polymorphism with risk of cervical cancer. Int J Biol Markers 24, 11-16 (2009).
26. Falleti, E. et al. Interleukin-6 polymorphisms and gender: relationship with the occurrence of hepatocellular carcinoma in patients with end-stage liver disease. Oncology 77, 304-313 (2009).
27. Cherel, M. et al. Molecular screening of interleukin-6 gene promoter and influence of -174G/C polymorphism on breast cancer. Cytokine 47, 214-223 (2009).
28. Birmann, B. M. et al. Insulin-like growth factor-1- and interleukin-6-related gene variation and risk of multiple myeloma. Cancer Epidemiol Biomarkers Prev 18, 282-288 (2009).
29. Andrie, E. et al. Genetic variants in immunoregulatory genes and risk for childhood lymphomas. Eur J Haematol 83, 334-342 (2009).
30. Aladzsity, I. et al. Comparative analysis of IL6 promoter and receptor polymorphisms in myelodysplasia and multiple myeloma. Leuk Res 33, 1570-1573 (2009).
31. Wilkening, S. et al. Interleukin promoter polymorphisms and prognosis in colorectal cancer. Carcinogenesis 29, 1202-1206 (2008).
32. Vogel, U. et al. Polymorphisms in genes involved in the inflammatory response and interaction with NSAID use or smoking in relation to lung cancer risk in a prospective study. Mutat Res 639, 89-100 (2008).
33. Vairaktaris, E. et al. Gene expression polymorphisms of interleukins-1 beta, -4, -6, -8, -10, and tumor necrosis factors-alpha, -beta: regression analysis of their effect upon oral squamous cell carcinoma. J Cancer Res Clin Oncol 134, 821-832 (2008).
34. Upadhyay, R., Jain, M., Kumar, S., Ghoshal, U. C. & Mittal, B. Association of interleukin-6 (-174G> C) promoter polymorphism with risk of squamous cell esophageal cancer and tumor location: an exploratory study. Clin Immunol 128, 199-204 (2008).
35. Slattery, M. L. et al. Modifying effects of IL-6 polymorphisms on body size-associated breast cancer risk. Obesity (Silver Spring) 16, 339-347 (2008).
36. Kesarwani, P., Ahirwar, D. K., Mandhani, A. & Mittal, R. D. Association between -174 G/C promoter polymorphism of the interleukin-6 gene and progression of prostate cancer in North Indian population. DNA Cell Biol 27, 505-510 (2008).
37. Ennas, M. G. et al. Interleukin-1B (IL1B) and interleukin-6 (IL6) gene polymorphisms are associated with risk of chronic lymphocytic leukaemia. Hematol Oncol 26, 98-103 (2008).
38. Crusius, J. B. et al. Cytokine gene polymorphisms and the risk of adenocarcinoma of the stomach in the European prospective investigation into cancer and nutrition (EPIC-EURGAST). Ann Oncol 19, 1894-1902 (2008).
39. Colakogullari, M. et al. The involvement of IL-10, IL-6, IFN-gamma, TNF-alpha and TGF-beta gene polymorphisms among Turkish lung cancer patients. Cell Biochem Funct 26, 283-290 (2008).
40. Bao, S., Yang, W., Zhou, S. & Ye, Z. Relationship between single nucleotide polymorphisms in -174G/C and -634C/G promoter region of interleukin-6 and prostate cancer. J Huazhong Univ Sci Technolog Med Sci 28, 693-696 (2008).
41. Ahirwar, D., Kesarwani, P., Manchanda, P. K., Mandhani, A. & Mittal, R. D. Anti- and proinflammatory cytokine gene polymorphism and genetic predisposition: association with smoking, tumor stage and grade, and bacillus Calmette-Guerin immunotherapy in bladder cancer. Cancer Genet Cytogenet 184, 1-8 (2008).
42. Vogel, U. et al. Peroxisome proliferator-activated [corrected] receptor-gamma2 [corrected] Pro12Ala, interaction with alcohol intake and NSAID use, in relation to risk of breast cancer in a prospective study of Danes. Carcinogenesis 28, 427-434 (2007).
43. Vogel, U. et al. Prospective study of interaction between alcohol, NSAID use and polymorphisms in genes involved in the inflammatory response in relation to risk of colorectal cancer. Mutat Res 624, 88-100 (2007).
44. Vishnoi, M. et al. Do TNFA -308 G/A and IL6-174 G/C gene polymorphisms modulate risk of gallbladder cancer in the north Indian population? Asian Pac J Cancer Prev 8, 567-572 (2007).
45. Litovkin, K. V., Domenyuk, V. P., Bubnov, V. V. & Zaporozhan, V. N. Interleukin-6-174G/C polymorphism in breast cancer and uterine leiomyoma patients: a population-based case control study. Exp Oncol 29, 295-298 (2007).
46. Gonullu, G. et al. Association of breast cancer and cytokine gene polymorphism in Turkish women. Saudi Med J 28, 1728-1733 (2007).
47. Slattery, M. L., Wolff, R. K., Herrick, J. S., Caan, B. J. & Potter, J. D. IL6 genotypes and colon and rectal cancer. Cancer Causes Control 18, 1095-1105 (2007).
48. Nearman, Z. P. et al. Immunogenetic factors determining the evolution of T-cell large granular lymphocyte leukaemia and associated cytopenias. Br J Haematol 136, 237-248 (2007).
49. Gatti, L. L. et al. Interleukin-6 polymorphisms, Helicobacter pylori infection in adult Brazilian patients with chronic gastritis and gastric adenocarcinoma. Arch Med Res 38, 551-555 (2007).
50. Duch, C. R. et al. Analysis of polymorphism at site -174 G/C of interleukin-6 promoter region in multiple myeloma. Braz J Med Biol Res 40, 265-267 (2007).
51. Deans, C. et al. Host cytokine genotype is related to adverse prognosis and systemic inflammation in gastro-oesophageal cancer. Ann Surg Oncol 14, 329-339 (2007).
52. Berkovic, M. C. et al. IL-6-174 C/G polymorphism in the gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Exp Mol Pathol 83, 474-479 (2007).
53. Vairaktaris, E. et al. Strong association of interleukin-6-174 G> C promoter polymorphism with increased risk of oral cancer. Int J Biol Markers 21, 246-250 (2006).
54. Theodoropoulos, G. et al. Relation between common polymorphisms in genes related to inflammatory response and colorectal cancer. World J Gastroenterol 12, 5037-5043 (2006).
55. Nogueira de Souza, N. C. et al. Interleukin-6 polymorphisms and the risk of cervical cancer. Int J Gynecol Cancer 16, 1278-1282 (2006).
56. Michaud, D. S. et al. Genetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer. Cancer Res 66, 4525-4530 (2006).
57. Kamangar, F. et al. Polymorphisms in inflammation-related genes and risk of gastric cancer (Finland). Cancer Causes Control 17, 117-125 (2006).
58. Gonzalez-Zuloeta Ladd, A. M. et al. Interleukin 6 G-174 C polymorphism and breast cancer risk. Eur J Epidemiol 21, 373-376 (2006).
59. Balasubramanian, S. P. et al. Interleukin gene polymorphisms and breast cancer: a case control study and systematic literature review. BMC Cancer 6, 188 (2006).
60. Rothman, N. et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol 7, 27-38 (2006).
61. Lan, Q. et al. Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood 107, 4101-4108 (2006).
62. Gunter, M. J. et al. Inflammation-related gene polymorphisms and colorectal adenoma. Cancer Epidemiol Biomarkers Prev 15, 1126-1131 (2006).
63. Gaustadnes, M., Orntoft, T. F., Jensen, J. L. & Torring, N. Validation of the use of DNA pools and primer extension in association studies of sporadic colorectal cancer for selection of candidate SNPs. Hum Mutat 27, 187-194 (2006).
64. Cozen, W. et al. Interleukin-6-related genotypes, body mass index, and risk of multiple myeloma and plasmacytoma. Cancer Epidemiol Biomarkers Prev 15, 2285-2291 (2006).
65. Snoussi, K., Strosberg, A. D., Bouaouina, N., Ben Ahmed, S. & Chouchane, L. Genetic variation in pro-inflammatory cytokines (interleukin-1beta, interleukin-1alpha and interleukin-6) associated with the aggressive forms, survival, and relapse prediction of breast carcinoma. Eur Cytokine Netw 16, 253-260 (2005).
66. Seifart, C. et al. TNF-alpha, TNF-beta, IL-6, and IL-10 polymorphisms in patients with lung cancer. Dis Markers 21, 157-165 (2005).
67. Migita, K. et al. Cytokine gene polymorphisms in Japanese patients with hepatitis B virus infection-association between TGFbeta1 polymorphisms and hepatocellular carcinoma. J Hepatol 42, 505-510 (2005).
68. Leibovici, D. et al. Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. J Clin Oncol 23, 5746-5756 (2005).
69. Hefler, L. A. et al. Interleukin-1 and interleukin-6 gene polymorphisms and the risk of breast cancer in caucasian women. Clin Cancer Res 11, 5718-5721 (2005).
70. Basturk, B. et al. Cytokine gene polymorphisms as potential risk and protective factors in renal cell carcinoma. Cytokine 30, 41-45 (2005).
71. Skerrett, D. L., Moore, E. M., Bernstein, D. S. & Vahdat, L. Cytokine genotype polymorphisms in breast carcinoma: associations of TGF-beta1 with relapse. Cancer Invest 23, 208-214 (2005).
72. Mazur, G. et al. IL-6 and IL-10 promoter gene polymorphisms do not associate with the susceptibility for multiple myeloma. Immunol Lett 96, 241-246 (2005).
73. Festa, F. et al. Basal cell carcinoma and variants in genes coding for immune response, DNA repair, folate and iron metabolism. Mutat Res 574, 105-111 (2005).
74. Cordano, P. et al. Effect of IL-6 promoter polymorphism on incidence and outcome in Hodgkin's lymphoma. Br J Haematol 128, 493-495 (2005).
75. Campa, D. et al. Lack of association between polymorphisms in inflammatory genes and lung cancer risk. Cancer Epidemiol Biomarkers Prev 14, 538-539 (2005).
76. Zhang, Z. et al. Use of pyrosequencing to detect clinically relevant polymorphisms of genes in basal cell carcinoma. Clin Chim Acta 342, 137-143 (2004).
77. Smith, K. C., Bateman, A. C., Fussell, H. M. & Howell, W. M. Cytokine gene polymorphisms and breast cancer susceptibility and prognosis. Eur J Immunogenet 31, 167-173 (2004).
78. Campa, D. et al. Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer. Carcinogenesis 25, 229-235 (2004).
79. Bushley, A. W. et al. Polymorphisms of interleukin (IL)-1alpha, IL-1beta, IL-6, IL-10, and IL-18 and the risk of ovarian cancer. Gynecol Oncol 95, 672-679 (2004).
80. Landi, S. et al. Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. Cancer Res 63, 3560-3566 (2003).
81. Hwang, I. R. et al. Interleukin-6 genetic polymorphisms are not related to Helicobacter pylori-associated gastroduodenal diseases. Helicobacter 8, 142-148 (2003).
82. Howell, W. M., Turner, S. J., Theaker, J. M. & Bateman, A. C. Cytokine gene single nucleotide polymorphisms and susceptibility to and prognosis in cutaneous malignant melanoma. Eur J Immunogenet 30, 409-414 (2003).
83. El-Omar, E. M. et al. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology 124, 1193-1201 (2003).
84. Zheng, C. et al. Interleukin 6, tumour necrosis factor alpha, interleukin 1beta and interleukin 1 receptor antagonist promoter or coding gene polymorphisms in multiple myeloma. Br J Haematol 109, 39-45 (2000).
85. Puchalski, T., Prabhakar, U., Jiao, Q., Berns, B. & Davis, H. M. Pharmacokinetic and pharmacodynamic modeling of an antiinterleukin- 6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma. Clin Cancer Res 16, 1652-1661 (2010).
86. Guo, Y., Xu, F., Lu, T., Duan, Z. & Zhang, Z. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 38, 904-910 (2012).
87. Jacobson, C. M., Rosenfeld, B., Pessin, H. & Breitbart, W. Depression and IL-6 blood plasma concentrations in advanced cancer patients. Psychosomatics 49, 64-66 (2008).
88. Mitsunaga, S. et al. Serum levels of IL-6 and IL-1beta can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 108, 2063-2069 (2013).
89. Salanti, G., Sanderson, S. & Higgins, J. P. Obstacles and opportunities in meta-analysis of genetic association studies. Genet Med 7, 13-20 (2005).
90. Zhou, X. C., Dowdy, S. C., Podratz, K. C. & Jiang, S. W. Epigenetic considerations for endometrial cancer prevention, diagnosis and treatment. Gynecol Oncol 107, 143-153 (2007).
91. Yu, K. et al. Methionine synthase A2756G polymorphism and cancer risk: a meta-analysis. Eur J Hum Genet 18, 370-378 (2010).
92. Pan, H. et al. Contributory role of five common polymorphisms of RAGE and APE1 genes in lung cancer among Han Chinese. PLoS One 8, e69018, doi:10.1371/journal.pone.0069018 (2013).
93. Moher, D., Liberati, A., Tetzlaff, J. & Altman, D. G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339, b2535 (2009).
94. Thakkinstian, A. et al. Systematic review and meta-analysis of the association between {beta}2-adrenoceptor polymorphisms and asthma: a HuGE review. Am J Epidemiol 162, 201-211 (2005).